Company intelligence / Profile preview
Navigator Medicines
Scotch Plains, New Jersey, United Statesnavigatormedicines.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
NAV-240 (formerly IMB101) is a clinical-stage bispecific antibody targeting OX40L and TNFα currently in Phase 1 development for complex autoimmune diseases. The dual targeting approach may improve upon the efficacy of either monotherapy alone.[2][6]
- Therapeutic areas
- Immunology
- Modalities
- Biologicsbispecific antibodiesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
IMBiologics Corp. (in-licensed NAV-240 and OX40L-targeted portfolio)[2][6]
Beyond the preview
Go deeper on Navigator Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navigator Medicines.